Stay updated on Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial

Sign up to get notified when there's something new on the Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    Recruitment messaging now shows 'No longer looking for participants', the treatment label is standardized to 'Intervention/Treatment' (replacing 'Intervention / Treatment'), several help/navigation links were added (How to Read a Study Record, Common Questions, How to Join a Study), and the revision badge updates from v3.5.4 to v3.6.0.
    Difference
    0.2%
    Check dated 2026-06-09T20:12:59.000Z thumbnail image
  3. Check
    18 days ago
    No Change Detected
  4. Check
    32 days ago
    Change Detected
    Summary
    Revision: v3.5.4 was added and the previous revision v3.5.3 was removed, indicating a small metadata update to the page.
    Difference
    0.0%
    Check dated 2026-05-19T09:56:59.000Z thumbnail image
  5. Check
    39 days ago
    Change Detected
    Summary
    A new bibliographic citation to a 2025 biomarker-driven study on metastatic gastric/GEJ cancer was added to Publications, expanding the referenced literature for the trial page.
    Difference
    0.0%
    Check dated 2026-05-12T08:20:25.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    The study locations are updated to reflect the renamed New Aquitaine region for Pessac and Poitiers, and the page revision is updated to v3.5.3.
    Difference
    0.1%
    Check dated 2026-04-27T20:10:47.000Z thumbnail image
  7. Check
    75 days ago
    Change Detected
    Summary
    Padua, Italy was removed and Padova, Italy was added in the study locations.
    Difference
    0.2%
    Check dated 2026-04-06T03:22:11.000Z thumbnail image
  8. Check
    89 days ago
    Change Detected
    Summary
    Added a Publication entry for the study: 'First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial' with PubMed attribution, including the author list and Naples, Italy affiliation.
    Difference
    0.2%
    Check dated 2026-03-22T22:01:55.000Z thumbnail image

Stay in the know with updates to Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial page.